ClinicalTrials.gg
TerminatedNCT04001543SIMPA01Updated Nov 9, 2026

Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

An interventional study of Immunomodulating oral supplementation and Sip feed control in Head and Neck Squamous Cell Carcinoma, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Terminated at 2 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
Updated Nov 9, 2026Now TerminatedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France — 46 open to participants now, 80 under way, 20 of them phase 3. Squamous Cell Carcinoma of Head and Neck · France.

Enrollment
174th of 197
27 · median 131
Started
2019
with 11 others
No phase
32 of 215
10 open now
Registered
112th of 215
by date

Among the 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France, this one is the 174th largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2019, is one of 32 with no phase, and was the 112th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

46 of the 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Squamous Cell Carcinoma of Head and Neck with a site in France, or all of them as a file.
02

Study summary

The investigators designed a prospective randomized double-blind trial to determine if the oral immunomodulating formula could improve the disease-free survival rate in high-risk locally-advanced head and neck Squamous Cell Carcinoma patients treated with Chemoradiotherapy.

Read the detailed description

The primary objective is to evaluate the efficacy on disease-free survival of a formula enriched with L-arginine, omega-3 fatty acids, and ribonucleic acids, taken for 5 days before each cycle of chemotherapy, in patients with high-risk locally-advanced HNSCC treated with postoperative concomitant chemoradiotherapy (CRT).

This study is a national, multicentric double blinded, randomised phase III trial. A total of 306 patients (102 patients in group control vs 204 patients in group Oral Impact®) will be required including 10% of lost-to-follow-up patients.

An immunomodulating oral supplementation compound (Oral Impact®) is compared to an isocaloric isonitrogenous control. The compound to be assessed contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3. The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients. Each patient has to take Oral Impact® or a sip feed control during 5 days before each cycle of chemotherapy.

DFS will be measured from the time of randomization to the time of the first evidence of progression (local, regional, metastatic, or second primary) or death from any cause. Patients alive without carcinologic event were censored at last follow-up date.

Patients treated with postoperative CRT are expected to have a 2-year DFS rate of 60% without specific diet (pControl).

Including a ratio 1:2, an expected recruitment of 90 patients per year, the current study will require 131 events to detect an absolute improvement of 15% (HR=0.56, pExperimental=75%) with 0.90 statistical power using a two-sided test and a significance level of 0.05.

A total of 306 patients (102 vs 204) will be required including 10% of lost of follow-up patients.

The inclusion period would be 4 years, for an expected total duration of study about 8 years.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • head and neck squamous cell carcinoma (HNSCC)
  • immunomodulatory nutrient
  • concomitant chemoradiotherapy
  • survival
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgically resected primary squamous cell carcinomas (HNSCC) of the hypopharynx, oropharynx, larynx and oral cavity with pathological stage pT1-2 pN+ (pathological stage 1 ou 2 with node) or pT3-4 any pN (pathological stage 3 ou 4 with or without node) (UICC 7th edition, 2010),
  • Postoperative concomitant CRT based on radiotherapy and on cisplatinum, 3 cycles, 100mg/m² by cycle,
  • Patients who undergone macroscopically complete resection,
  • High-risk characteristics patients with one or more following criteria: such as invasion of two or more regional lymph nodes, extracapsular extension of nodal disease or microscopically-involved mucosal margins of resection, perineural involvement, vascular tumor embolism,
  • WHO (World Health Organization) performance status 0, 1 or 2,
  • Age: 18 years old up to 75 years old including,

Exclusion criteria

Exclusion Criteria:

  • Nasopharyngeal, paranasal sinuses, nasal cavity tumours or thyroid cancers
  • Sepsis at baseline
  • Distant
  • Other immunomodulating diets in the last month before inclusion
  • Parenteral nutrition at baseline
  • History of and/or allergy to any component of Oral Impact ®
  • Patients with history of who are not disease-free for more than 5 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Immunomodulating oral supplementation

    The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3. Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle.

    Dietary Supplement: Immunomodulating oral supplementation

  • Active comparator
    Sip feed control

    The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control. Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle.

    Dietary Supplement: Sip feed control

Interventions

  • Dietary supplementImmunomodulating oral supplementation

    Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.

  • Dietary supplementSip feed control

    Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS)

    2-years DFS rate

    Time frame: From date of randomization until the date of the first documented progression (local, regional, metastatic) or date of death from any cause, whichever came first, assessed up to 2 years.

Secondary outcomes

  1. Overall Survival (OS)

    OS at 1, 2 and 3 years

    Time frame: From date of randomization until the date of death from any cause, assessed up to 3 years.

  2. Rate of drug compliance

    the compliance is defined as the taking of more than 75 % of study product prescription

    Time frame: up to 45 days

  3. Adverse events rate

    graded based on NCI-CTCAE v4.03

    Time frame: until 3 months after radiotherapy

  4. Quality of life by using the general quality of life questionnaire about cancer (QLQ-C30).

    The EORTC QLQ-C30 uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated with mean values. Afterwards linear transformation is performed to be comparable. More points are considered to have a better outcome.

    Time frame: Quality of life will be assessed up to 2 years after the last day of radiotherapy.

  5. Quality of life by using the specific quality of life questionnaire about head and neck cancer (HN35)

    The EORTC HN35 uses a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.

    Time frame: Quality of life will be assessed up to 2 years after the last day of radiotherapy.

  6. Cachexia

    Cachexia will be evaluated with weight (in kilograms)

    Time frame: Cachexia will be assessed up to 3 years after the last day of radiotherapy.

07

Study locations

2 sites
08

References and documents

Publications

  • Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. doi: 10.1056/NEJMoa032646. PubMed 15128893 ↗
  • Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52. doi: 10.1056/NEJMoa032641. PubMed 15128894 ↗
  • Machon C, Thezenas S, Dupuy AM, Assenat E, Michel F, Mas E, Senesse P, Cristol JP. Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients. Support Care Cancer. 2012 Dec;20(12):3129-35. doi: 10.1007/s00520-012-1444-5. Epub 2012 Mar 28. PubMed 22453793 ↗
  • Vasson MP, Talvas J, Perche O, Dillies AF, Bachmann P, Pezet D, Achim AC, Pommier P, Racadot S, Weber A, Ramdani M, Kwiatkowski F, Bouteloup C. Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial. Clin Nutr. 2014 Apr;33(2):204-10. doi: 10.1016/j.clnu.2013.06.008. Epub 2013 Jun 20. PubMed 23849811 ↗
  • De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003 Dec;2(4):323. doi: 10.1016/S1474-5151(03)00091-4. No abstract available. PubMed 14667488 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2019 to primary completion in Mar 2021, 23 months.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2024, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 28, 2019
StartActual
Mar 14, 2019
Primary completionActual
Mar 2, 2021
CompletionActual
Jun 11, 2024was May 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
changed Nov 9, 2026
Study completion
May 2026→Jun 11, 2024 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Terminated
    Why stopped A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.
    Study completion May 2026→Jun 11, 2024 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04001543
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Mar 14, 2019
Primary completion
Mar 2, 2021
Completion
Jun 11, 2024
Last update
Nov 9, 2026

Study contacts

Pierre SENESSE, MD
study chair · Institut du Cancer de Montpellier - Val d'Aurelle

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion